Inceptor Bio is developing OUTLAST™ CAR T cell therapies that reprogram T cells to maintain a stem-like, durable anti-tumor phenotype, enhancing their effectiveness against solid tumors. This approach addresses the challenge of T cell exhaustion and immune suppression in aggressive cancer environments, aiming to improve patient outcomes through sustained therapeutic activity.
Funding
$59.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
CAR-T therapies have demonstrated success in hematological malignancies, but they often lack durable responses in solid tumors due to the immunosuppressive tumor microenvironment (TME). The TME causes T cell exhaustion, metabolic stress, and stifled T cell responses, limiting the effectiveness of CAR-T therapies in solid tumors, which represent 90% of cancer cases.
Solution
Inceptor Bio is developing OUTLAST™ CAR T cell therapies, a platform designed to overcome the challenges posed by the solid tumor microenvironment. The OUTLAST™ platform replicates the harsh conditions of the TME during cell manufacturing to metabolically reprogram T cells. This reprogramming enhances T cell persistence, metabolic fitness, and resistance to exhaustion, enabling the CAR T cells to maintain a stem-like, durable anti-tumor phenotype. By integrating proprietary technology, Inceptor Bio aims to improve patient outcomes through sustained therapeutic activity in aggressive cancer environments.
Target Audience
The primary target audience includes patients with solid tumor cancers, as well as oncologists and medical professionals seeking more effective cell therapies for these difficult-to-treat cancers.
Features
- OUTLAST™ CAR T cells exhibit superior activation and resist exhaustion even after long-term activity in vivo.
- Upregulates genes associated with long-lived, persistent, stem-like early memory cells.
- Suppresses genes associated with short-lived, terminally differentiated effector cells and T cell exhaustion.
- Proprietary technology reprograms T cells into a stem-like, durable anti-tumor phenotype.
- IB-T101 is the first therapeutic developed using the OUTLAST™ platform and is currently in clinical trials.